An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a one-year, double-blind, randomized trial.

被引：0
|
作者：
Mastey, V
Wimo, A
Winblad, B
Haglund, A
Jacobson, L
Miceli, R
Zhang, R
Subbiah, P
机构：
[1] Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY USA
[2] Umea Univ, Dept Family Med, Umea, Sweden
[3] Karolinska Inst, Huddinge, Sweden
[4] Pfizer AB, Taby, Sweden
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2001年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P382
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [1] An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial
    Wimo, A
    Winblad, B
    Engedal, K
    Soininen, H
    Verhey, F
    Waldemar, G
    Wetterholm, AL
    Mastey, V
    Haglund, A
    Zhang, R
    Miceli, R
    Chin, W
    Subbiah, P
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (01) : 44 - 54
  • [2] Donepezil reduces the time caregivers spend providing care: Results of a one-year, double-blind randomized trial in patients with mild to moderate Alzheimer's disease.
    Mastey, V
    Wimo, A
    Winblad, B
    Haglund, A
    Jacobson, L
    Miceli, R
    Zhang, R
    Subbiah, P
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S20 - S20
  • [3] An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial (vol 15, pg 44, 2003)
    Wimo
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 16 (02) : 102 - 102
  • [4] Treatment with Cerebrolysin, donepezil and a combination therapy in mild to moderate Alzheimer's disease: a double-blind clinical trial
    Alvarez, A.
    Sampedro, C.
    Couceiro, V.
    Cacabelos, R.
    Garcia-Fantini, M.
    Aleixandre, M.
    Linares, C.
    Granizo, E.
    Doppler, E.
    Novak, P.
    Moessler, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 342 - 342
  • [5] A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    [J]. NEUROLOGY, 2001, 57 (04) : 613 - 620
  • [6] Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
    Gu, Jiachen
    Li, Zongshan
    Chen, Huimin
    Xu, Xiaomin
    Li, Yongang
    Gui, Yaxing
    [J]. NEUROLOGY AND THERAPY, 2021, 10 (02) : 905 - 917
  • [7] Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
    Jiachen Gu
    Zongshan Li
    Huimin Chen
    Xiaomin Xu
    Yongang Li
    Yaxing Gui
    [J]. Neurology and Therapy, 2021, 10 : 905 - 917
  • [8] Dimebon Improves Cognition, Function, and Behavior in Patients With Mild or Moderate Alzheimer's Disease: Results by Disease Severity of a 1-Year Double-Blind, Placebo-Controlled Trial.
    Doody, R.
    Sano, M.
    Aisen, P.
    Seely, L.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 : S122 - S123
  • [9] The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
    Rogers, SL
    Friedhoff, LT
    Apter, JT
    Richter, RW
    Hartford, JT
    Walshe, TM
    Baumel, B
    Linden, RD
    Kinney, FC
    Doody, RS
    Borison, RL
    Ahem, GL
    [J]. DEMENTIA, 1996, 7 (06): : 293 - 303
  • [10] Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study
    Zhang, Zhenxin
    Yu, Lu
    Gaudig, Maren
    Schaeuble, Barbara
    Richarz, Ute
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 571 - 577
12345